MCID: CHR466
MIFTS: 34

Chronic Thromboembolic Pulmonary Hypertension malady

Categories: Respiratory diseases, Rare diseases, Blood diseases

Aliases & Classifications for Chronic Thromboembolic Pulmonary Hypertension

About this section
Sources:
51Orphanet, 65UMLS, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Chronic Thromboembolic Pulmonary Hypertension:

Name: Chronic Thromboembolic Pulmonary Hypertension 51 65
 
Cteph 51

Characteristics:

Orphanet epidemiological data:

51
chronic thromboembolic pulmonary hypertension:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Adult

Classifications:



External Ids:

Orphanet51 70591
UMLS via Orphanet66 C2363973
UMLS65 C2363973

Summaries for Chronic Thromboembolic Pulmonary Hypertension

About this section
MalaCards based summary: Chronic Thromboembolic Pulmonary Hypertension, also known as cteph, is related to heart disease and thyroid cancer. An important gene associated with Chronic Thromboembolic Pulmonary Hypertension is FGA (Fibrinogen Alpha Chain), and among its related pathways are Cardiomyocyte Differentiation through BMP Receptors and MicroRNAs in cardiomyocyte hypertrophy. Affiliated tissues include heart, lung and breast, and related mouse phenotype cardiovascular system.

Related Diseases for Chronic Thromboembolic Pulmonary Hypertension

About this section

Diseases related to Chronic Thromboembolic Pulmonary Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 356)
idRelated DiseaseScoreTop Affiliating Genes
1heart disease29.8CRP, EDN1, NPPB
2thyroid cancer29.4CRP, EDN1, PTGIS
3myocardial infarction29.3CRP, FGA, NPPB, PTGIS
4breast cancer10.5
5hepatitis10.4
6leukemia10.4
7arthritis10.3
8pancreatitis10.3
9endotheliitis10.3
10lung cancer10.3
11hiv-110.3
12prostate cancer10.3
13obesity10.3
14q fever10.3
15down syndrome10.3
16prostatitis10.3
17cervicitis10.3
18cerebritis10.3
19pneumonia10.3
20thyroiditis10.3
21rheumatoid arthritis10.2
22malaria10.2
23angelman syndrome10.2
24bronchiolitis obliterans10.2
25burns10.2
26glomerulonephritis10.2
27usher syndrome10.2
28lymphoma10.2
29alexithymia10.2
30apraxia10.2
31erysipelas10.2
32esophagitis10.2
33gynecomastia10.2
34urethritis10.2
35urticaria10.2
36melanoma10.2
37papilloma10.2
38bronchiolitis10.2
39adenocarcinoma10.2
40inverted papilloma10.2
41laryngitis10.2
42retinitis10.2
43congenital diaphragmatic hernia10.2
44myopathy10.2
45dystonia10.2
46vipoma10.2
47adenoma10.2
48hepatoblastoma10.2
49diverticulitis10.2
50neuronitis10.2

Graphical network of the top 20 diseases related to Chronic Thromboembolic Pulmonary Hypertension:



Diseases related to chronic thromboembolic pulmonary hypertension

Symptoms for Chronic Thromboembolic Pulmonary Hypertension

About this section

Drugs & Therapeutics for Chronic Thromboembolic Pulmonary Hypertension

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Adempas15 RIOCIGUAT Bayer Healthcare Pharmaceuticals October 2013
FDA Label: Adempas
Disease/s that Drug Treats:Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Indications and Usage:15 Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: * Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. (1.1) * Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. (1.2)
DrugBank Targets: -
Mechanism of Action:15 
Target: soluble guanylate cyclase (sGC)
Action: stimulator
FDA: Riociguat is a stimulator of soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system and the receptor for nitric oxide (NO). When NO binds to sGC, the enzyme catalyzes synthesis of the signaling molecule cyclic guanosine monophosphate (cGMP). Intracellular cGMP plays an important role in regulating processes that influence vascular tone, proliferation, fibrosis and inflammation.Pulmonary hypertension is associated with endothelial dysfunction, impaired synthesis of nitric oxide and insufficient stimulation of the NO-sGC-cGMP pathway. Riociguat has a dual mode of action. It sensitizes sGC to endogenous NO by stabilizing the NO-sGC binding. Riociguat also directly stimulates sGC via a different binding site, independently of NO. Riociguat stimulates the NO-sGC-cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation. The active metabolite (M1) of riociguat is 1/3 to 1/10 as potent as riociguat.

Drugs for Chronic Thromboembolic Pulmonary Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Bosentanapproved, investigationalPhase 3100147536-97-8104865
Synonyms:
-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide
147536-97-8
174227-18-0
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl) benzenesulfornamide
4-(1,1-Dimethylethyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl)benzenesulfornamide
4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl)benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2'-bipyrimidin-4-yl]benzenesulfonamide
4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide
AC-148
AC1L2XN2
Actelion
Bosentan
Bosentan (INN)
Bosentan [USAN:INN:BAN]
Bosentan hydrate
Bosentanum
C27H29N5O6S
CHEBI:51450
CHEMBL957
CID104865
D07538
 
DB00559
EN002863
HMS2090N14
I06-1873
KS-5062
L001086
LS-31532
MolPort-003-845-300
NCGC00167440-01
P-Tert-butyl-N-(6-(2-hydroxyethoxy)-5-(O-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
PDSP1_001731
PDSP2_001714
Ro 47-0203
Ro 47-0203/039
Ro-47-0203
Ro-47-0203/029
Ro-47-0203/039
TL8001039
Tracleer
UNII-XUL93R30K2
bosentanum
p-tert-Butyl-N-(6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl)benzenesulfonamide
p-tert-Butyl-N-[6-(2-hydroxyethoxy)
2
Treprostinilapproved, investigationalPhase 37781846-19-754786, 6918140
Synonyms:
((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate
(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid
15 AU81
15AU81
2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
289480-64-4 (Sodium salt)
81846-19-7
AC1L1HPX
AC1OCF2J
CHEBI:50861
CID11246284
CID54786
CID6918140
CID9800580
D06213
DB00374
L001079
LRX 15
 
LS-177654
LS-187014
LS-187645
Orenitram
Remodulin
Remodulin (TN)
Treprostinil
Treprostinil (USAN/INN)
Treprostinil [USAN:INN]
Treprostinil sodium
Treprostinilo
Treprostinilum
Tyvaso
U 62840
U-62,840
UNII-RUM6K67ESG
UT-15
Uniprost
Viveta
[[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
treprostinilo
treprostinilum
3Endothelin Receptor AntagonistsPhase 3, Phase 2189
4Antihypertensive AgentsPhase 33618
5CalamusNutraceuticalPhase 3344
6
MacitentanapprovedPhase 229441798-33-0
Synonyms:
ACT 064992
ACT-064992
 
ACT064992
Macitentanum
OPSUMIT
Opsumit
7adrenomedullinPhase 211
8Fluorodeoxyglucose F18Phase 2356
9Endothelin A Receptor AntagonistsPhase 232
10
Warfarinapproved42281-81-26691, 54678486
Synonyms:
(-)-Warfarin
(S)-4-hydroxy-3-(3-oxo-1-phenylbutyl)-2-benzopyrone
(S)-Warfarin
(phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarin
(phenyl-1 acetyl-2 ethyl) 3-hydroxy-4 coumarine
1-(4'-Hydroxy-3'-coumarinyl)-1-phenyl-3-butanone
200 Coumarin
200 coumarin
3-(1'-Phenyl-2'-acetylethyl)-4-hydroxycoumarin
3-(Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Acetonylbenzyl)-4-hydroxycoumarin
3-(alpha-Phenyl-beta-acetylaethyl)-4-hydroxycumarin
3-(alpha-Phenyl-beta-acetylethyl)-4-hydroxycoumarin
4-Hydroxy-3- (3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3- (3-oxo-1-phenyl-butyl)-cumarin
4-Hydroxy-3-(3-oxo-1-fenyl-butyl) cumarine
4-Hydroxy-3-(3-oxo-1-phenyl-butyl)-cumarin
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one
4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin
4-Idrossi-3- (3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-)-fenil-butil)-cumarine
4-Idrossi-3-(3-oxo-1-fenil-butil)-cumarine
45706_FLUKA
45706_RIEDEL
4oh-coumarin deriv.
5543-56-6
5543-57-7
81-81-2
A2250_FLUKA
A2250_SIGMA
AC-15978
AC1L1N37
AC1Q6AN3
AR-1E2310
Arab Rat Death
Arab rat death
Arab rat deth
Athrombin
Athrombin-K
Athrombin-k
Athrombine-K
Athrombine-k
BRD-A24514565-001-02-2
BRD-A24514565-236-01-6
BRN 1293536
BSPBio_002026
Bio-0586
Brumolin
C01541
C19H16O4
CBDivE_002127
CBDivE_013236
CBKinase1_000192
CBKinase1_012592
CHEBI:10033
CHEMBL1464
CID6691
CO-Rax
Caswell No. 903
Choice
Choice (TN)
Co-Rax
Co-rax
Compound 42
Coumadin
Coumadin Tabs
Coumafen
Coumafene
Coumafene [French]
Coumaphen
Coumaphene
Coumarins
Coumefene
Cov-R-Tox
Cov-R-tox
D-Con
D08682
DB00682
DL-3-(alpha-acetonylbenzyl)-4-hydroxycoumarin
Dethmor
Dethnel
Dicusat E
Dicusat e
DivK1c_000444
EINECS 201-377-6
EINECS 226-907-3
EPA Pesticide Chemical Code 086002
Eastern states duocide
Fasco fascrat powder
Frass-Ratron
Frass-ratron
HMS1921K07
HMS2092C20
HMS501G06
HSDB 1786
I14-0958
IDI1_000444
Jantoven
KBio1_000444
KBio2_000674
KBio2_003242
KBio2_005810
KBio3_001526
KBioGR_000901
KBioSS_000674
Killgerm sewarin p
Kumader
Kumadu
Kumatox
Kypfarin
LS-55083
Latka 42
Latka 42 [Czech]
Liqua-tox
MLS001304042
Maag Rattentod Cum
Maag rattentod cum
Mar-Frin
Mar-frin
Marevan
Martin'S mar-frin
Martin's mar-frin
 
Maveran
MolPort-001-787-822
Mouse pak
NCGC00094810-01
NCGC00094810-02
NCGC00159398-03
NCGC00178855-01
NINDS_000444
NSC 59813
NSC59813
PS104_SUPELCO
Panwarfin
Place-Pax
Place-pax
Prothromadin
RAX
RCR grey squirrel killer concentrate
RCRA waste no. P001
Rat & mice bait
Rat and mice bait
Rat-B-gon
Rat-Gard
Rat-Kill
Rat-Mix
Rat-O-cide #2
Rat-O-cide no. 2
Rat-Ola
Rat-Trol
Rat-a-way
Rat-alpha-way
Rat-b-gon
Rat-beta-gon
Rat-gard
Rat-kill
Rat-mix
Rat-o-cide #2
Rat-ola
Rat-trol
Ratorex
Ratox
Ratoxin
Ratron
Ratron G
Ratron g
Rats-no-more
Ratten-Koederrohr
Ratten-koederrohr
Rattenstreupulver Neu Schacht
Rattenstreupulver neu schacht
Rattenstreupulver new schacht
Rattentraenke
Rattunal
Rcra waste number P001
Ro-Deth
Ro-deth
Rodafarin
Rodafarin C
Rodafarin c
Rodex
Rodex blox
Rosex
Rough & ready mouse mix
Rough and ready mouse mix
SMP1_000316
SMR000718754
SPBio_000870
SPECTRUM1500613
STK364490
Sakarat
Sewarin
Sofarin
Solfarin
Sorexa Plus
Sorexa plus
Spectrum2_000935
Spectrum3_000583
Spectrum4_000381
Spectrum5_001751
Spectrum_000194
Spray-trol brand roden-trol
Temus W
Temus w
Tintorane
Tox-Hid
Tox-hid
Twin light rat away
UNII-5Q7ZVV76EI
Vampirinip II
Vampirinip III
Vampirinip iii
W.A.R.F. 42
WARF compound 42
WLN: T66 BOVJ DYR&1V1 EQ
Waran
Warf 10
Warf 42
Warfarat
Warfarin (INN)
Warfarin (and salts of)
Warfarin Plus
Warfarin Q
Warfarin Sodium
Warfarin [BSI:ISO]
Warfarin [INN:BAN]
Warfarin plus
Warfarin plus [discontinued]
Warfarin sodium
Warfarin titrated to an INR of 2.5-3.0
Warfarin(R)
Warfarina
Warfarina [INN-Spanish]
Warfarine
Warfarine [INN-French]
Warfarine [ISO-French]
Warfarinum
Warfarinum [INN-Latin]
Warficide
Warfilone
Zoocoumarin
Zoocoumarin [Netherlands and USSR]
Zoocoumarin [Russian]
delta-Con
nchembio.307-comp19
rac-Warfarin
warfarin
11
Rivaroxabanapproved215366789-02-8
Synonyms:
BAY 59-7939
 
BAY59-7939
Xarelto
12
Iloprostapproved, investigational7478919-13-86443959
Synonyms:
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5Z)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
73873-87-7
78919-13-8
AC1NSK5T
AC1O5JIJ
AC1O5JP3
AC1Q1J28
ACT-213105
C22H32O4
CHEMBL138694
CHEMBL236025
CHEMBL494
CID10937300
CID11639089
CID5311181
CID6435293
CID6435378
CID9885245
 
CID9975807
Ciloprost
D02721
E-1030
Endoprost
HMS2090A19
ILOPROST
Ilomedin
Ilomedine
Iloprost
Iloprost (INN)
Iloprost [BAN:INN]
Iloprostum
Iloprostum [Latin]
L000996
LS-101845
NCGC00181784-01
PDSP2_001536
SH-401
UNII-JED5K35YGL
Ventavis
Ventavis (TN)
ZK 36374
ZK-36374
ZK-363775
[3H]-Iloprost
13
Tadalafilapproved, investigational140171596-29-5110635
Synonyms:
(6R,12AR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-(methylenedioxy)phenyl) pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R,12aR)-2,3,6,7,12,12a-Hexahydro-2-methyl-6-(3,4-methylenedioxyphenyl)pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
(6R-trans)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-pyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
171596-29-5
1xoz
6-BENZO[1,3]dioxol-5-yl-2-methyl-2,3,6,7,12,12a-hexahydro-pyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
AC1L380B
ADCIRCA
Acdirca
Adcirca
C429886
CHEBI:41488
CHEMBL779
CID110635
CPD000466321
Cialis
Cialis (TN)
Cialis, GF 196960, IC 351, ICOS 351, Tadalafil
D02008
DB00820
FT-0080116
GF 196960
GF-196960
 
HMS2051N17
HSDB 7303
IC 351
IC-351
ICOS 351
Ic351
KS-1117
LS-186558
LS-187015
LS-187770
Lilly brand of tadalafil
MLS000759426
MLS001165782
MLS001195644
MLS001424132
MolPort-002-885-864
S1512_Selleck
SAM001246586
SMR000466321
Tadalafil
Tadalafil (JAN/USAN/INN)
Tadalafil [USAN]
Tadanafil
UNII-742SXX0ICT
ZINC03993855
14Serine Proteinase Inhibitors705
15Protease Inhibitors4558
16Antithrombins574
17Anticoagulants1760
18HIV Protease Inhibitors4558
19Antithrombin III563
20Factor Xa Inhibitors315
21Immunoglobulins4477
22Antibodies4477
23Tezosentan64
24Autoantibodies117
25Phosphodiesterase Inhibitors1062
26Sildenafil Citrate304171599-83-0
27Phosphodiesterase 5 Inhibitors513
28serineNutraceutical770

Interventional clinical trials:

(show top 50)    (show all 51)
idNameStatusNCT IDPhase
1Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.CompletedNCT01884675Phase 3
2Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary HypertensionCompletedNCT00313222Phase 3
3Bosentan in Patients With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)CompletedNCT00319111Phase 3
4A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)CompletedNCT01894022Phase 3
5A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.CompletedNCT00855465Phase 3
6Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH)RecruitingNCT01416636Phase 3
7Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary HypertensionRecruitingNCT01884012Phase 3
8Influence of Respiratory and Exercise Therapy on Oxygen Uptake and Right Heart Function in CTEPH Patients After PEARecruitingNCT01393327Phase 3
9BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary HypertensionActive, not recruitingNCT00910429Phase 3
10An Open Multiple Dose Titration Study In Patients With Pulmonary HypertensionCompletedNCT00454558Phase 2
11Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary HypertensionCompletedNCT02216279Phase 2
12Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary HypertensionRecruitingNCT02060721Phase 2
13Effect of Short-term Oxygen During CPET in Pulmonary HypertensionRecruitingNCT01748474Phase 2
14Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.RecruitingNCT01953965Phase 2
15Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary HypertensionActive, not recruitingNCT02021292Phase 2
16Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPHActive, not recruitingNCT02094001Phase 2
17Lung Protective Ventilation in Pulmonary Thromboendarterectomy (PTE) PatientsCompletedNCT00747045
18Study on the Clinical Course Of Pulmonary EmbolismCompletedNCT01781858
19Identification of Criteria of the Success of the Endarterectomy in Chronic Pulmonary Post Embolic HypertensionCompletedNCT00657722
20Smoking: a Risk Factor for Pulmonary Arterial Hypertension?CompletedNCT01484899
21RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter DefibrillatorsCompletedNCT02111980
22Prospective Registry to Evaluate the Effective Incidence of Chronic Thromboembolic Pulmonary Hypertension in GermanyRecruitingNCT02660463
23Registry for Pulmonary Hypertension in ChinaRecruitingNCT01417338
24Latent Pulmonary Hypertension (PH) in Chronic Thromboembolic Pulmonary Hypertension (CTEPH )After Endarterectomy and Influence of Exercise and Respiratory TherapyRecruitingNCT00477724
25Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET ImagingRecruitingNCT02114047
26U.S. CTEPH RegistryRecruitingNCT02429284
27A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical PracticeRecruitingNCT02545465
28Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH)RecruitingNCT02117791
29A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA CountriesRecruitingNCT02637050
30Long Term Outcomes of Venous ThromboembolismRecruitingNCT02268630
31New International CTEPH DatabaseRecruitingNCT02656238
32Electronic Activity Level Monitoring Pilot in Pulmonary HypertensionRecruitingNCT02536534
33Effect of Exercise Training in Patients With Pulmonary HypertensionRecruitingNCT02558582
34Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP TreatmentRecruitingNCT02583906
35Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary ThromboendarterectomyRecruitingNCT02745106
36Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Incidence in Patients With Central Versus Peripheral EmbolismRecruitingNCT01672203
37Epidemiological Study of Chronic Thromboembolic Pulmonary Hypertension in ChinaRecruitingNCT01717092
38Follow-up in Rivaroxaban Patients in Setting of ThromboembolismRecruitingNCT02248610
39Global Anticoagulant Registry in the FIELD- Venous Thromboembolic EventsRecruitingNCT02155491
40Gene Mutations in Secondary Pulmonary HypertensionRecruitingNCT00348803
41Zürich Pulmonary Hypertension Outcome Assessment CohortRecruitingNCT02249806
42EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary HypertensionRecruitingNCT02092818
43VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTERecruitingNCT02156401
44Exhaled Breath Olfactory Signature of Pulmonary Arterial HypertensionRecruitingNCT02782026
45Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term OutcomeActive, not recruitingNCT02565030
46Auto-immunity and Pulmonary Arterial HypertensionActive, not recruitingNCT01208792
47Right Ventricular Resynchronization TherapyEnrolling by invitationNCT01163422
48Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary HypertensionNot yet recruitingNCT02634203
49Early Non-invasive Detection of CTEPH After Pulmonary EmbolismNot yet recruitingNCT02555137
503D Echocardiographic Assessment of RV Function in Patients Undergoing Pulmonary EndarterectomyNot yet recruitingNCT02426203

Search NIH Clinical Center for Chronic Thromboembolic Pulmonary Hypertension

Genetic Tests for Chronic Thromboembolic Pulmonary Hypertension

About this section

Anatomical Context for Chronic Thromboembolic Pulmonary Hypertension

About this section

MalaCards organs/tissues related to Chronic Thromboembolic Pulmonary Hypertension:

33
Heart, Lung, Breast, Liver, Endothelial, Bone, B cells

Animal Models for Chronic Thromboembolic Pulmonary Hypertension or affiliated genes

About this section

MGI Mouse Phenotypes related to Chronic Thromboembolic Pulmonary Hypertension:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053857.6BMPR2, CRP, EDN1, FGA, PTGIS

Publications for Chronic Thromboembolic Pulmonary Hypertension

About this section

Articles related to Chronic Thromboembolic Pulmonary Hypertension:

(show top 50)    (show all 444)
idTitleAuthorsYear
1
A Central Role for Sympathetic Nerves in Herpes Stromal Keratitis in Mice. (27070108)
2016
2
Targeting of Carbon Ion-Induced G2 Checkpoint Activation in Lung Cancer Cells Using Wee-1 Inhibitor MK-1775. (26645158)
2015
3
Human sparganosis, a neglected food borne zoonosis. (26364132)
2015
4
PDX1 binds and represses hepatic genes to ensure robust pancreatic commitment in differentiating human embryonic stem cells. (25843046)
2015
5
Trichoscopy in trichotillomania: a useful diagnostic tool. (25368471)
2014
6
Symptom prevalence, frequency, severity, and distress during chemotherapy for patients with colorectal cancer. (24337684)
2013
7
MicroRNA expression and JAK2 allele burden in bone marrow trephine biopsies of polycythemia vera, essential thrombocythemia and early primary myelofibrosis. (23343777)
2013
8
Impact of the positive pathergy test on the performance of classification/diagnosis criteria for Behcet's disease. (22476858)
2013
9
MCP-1 induced protein promotes adipogenesis via oxidative stress, endoplasmic reticulum stress and autophagy. (22739135)
2012
10
Unique and atypical deletions in Prader-Willi syndrome reveal distinct phenotypes. (22045295)
2012
11
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. (22057838)
2012
12
Expression of nucleophosmin in glandular epithelium of non-pregnant human endometrium during the menstrual cycle. (21933585)
2011
13
A common genetic variant in the 3'-UTR of vacuolar H+-ATPase ATP6V0A1 creates a micro-RNA motif to alter chromogranin A processing and hypertension risk. (21558123)
2011
14
Hypoadrenalism presenting as a range of mental disorders. (22707626)
2011
15
Number of flocks on the same litter and carcase condemnations due to cellulitis, arthritis and contact foot-pad dermatitis in broilers. (21058060)
2010
16
Pentameric assembly of potassium channel tetramerization domain- containing protein 5. (19361449)
2009
17
Antibodies to enzymes of purine metabolism as a factor of gastrointestinal tract lesions in systemic scleroderma]. (19551958)
2009
18
Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. (19302581)
2009
19
Interaction between cFLIP and Itch, a ubiquitin ligase, is obstructed in Trypanosoma cruzi-infected human cells. (19090833)
2008
20
Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. (18635812)
2008
21
Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. (17564968)
2007
22
Pharmacogenetics of glucose-lowering drug treatment: a systematic review. (17963417)
2007
23
Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure). (17700397)
2007
24
Cell density-dependent nuclear/cytoplasmic localization of NORPEG (RAI14) protein. (16729964)
2006
25
Glutamate carboxypeptidase II (NAALADase) inhibition as a novel therapeutic strategy. (16802724)
2006
26
GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. (17169172)
2006
27
Relationship between serum adiponectin concentration, pulse wave velocity and nonalcoholic fatty liver disease. (15745930)
2005
28
Oncostatin M induces proliferation of human adipose tissue-derived mesenchymal stem cells. (15979922)
2005
29
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. (15262123)
2004
30
Effects of mitogen-activated protein kinase on phorbol 12-myristate 13-acetate-induced matrix metalloproteinase-9 gene expression in cytotrophoblastic cells]. (15041541)
2004
31
Simple closure of chronic duodenal ulcer perforation in the era of Helicobacter pylori: an old procedure, today's solution. (14571746)
2003
32
Rad54 protein exerts diverse modes of ATPase activity on duplex DNA partially and fully covered with Rad51 protein. (12359723)
2002
33
Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. (11804670)
2002
34
Espin contains an additional actin-binding site in its N terminus and is a major actin-bundling protein of the Sertoli cell-spermatid ectoplasmic specialization junctional plaque. (10588661)
1999
35
Presence of enolase in the M-band of skeletal muscle and possible indirect interaction with the cytosolic muscle isoform of creatine kinase. (9931306)
1999
36
Characterization of interactions of Nck with Sos and dynamin. (10206341)
1999
37
Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia. (9617462)
1998
38
Cow's milk-protein allergy as a cause of anal fistula and fissures: a case report. (9449512)
1998
39
The frequency of cells secreting interferon-gamma and interleukin-4, -5, and -10 in the blood and duodenal mucosa of children with cow's milk hypersensitivity. (9357936)
1997
40
A primary adenosquamous carcinoma of the liver with an elevated level of serum squamous cell carcinoma related antigen. (8799411)
1996
41
Altered rate of fibronectin matrix assembly by deletion of the first type III repeats. (8707839)
1996
42
Recent studies in bladder cancer. (7654832)
1995
43
Isozyme-selective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutic potential in asthma. (8395068)
1993
44
Analysis of uncoupling protein and its mRNA in adipose tissue deposits of adult humans. (1319974)
1992
45
Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate. (1580062)
1992
46
Regulated expression of globin chains and the erythroid transcription factor GATA-1 during erythropoiesis in the developing mouse. (1701019)
1990
47
Serum lithium concentrations and peripheral leukocytes in a case of leukopenia. (3741920)
1986
48
Severe congenital factor X deficiency with intracranial haemorrhage. (3732313)
1986
49
Abetalipoproteinemia. Report of an unusual patient. (6472810)
1984
50
Developmental aspects of sirenomelia in the mouse. (4753445)
1973

Variations for Chronic Thromboembolic Pulmonary Hypertension

About this section

Expression for genes affiliated with Chronic Thromboembolic Pulmonary Hypertension

About this section
Search GEO for disease gene expression data for Chronic Thromboembolic Pulmonary Hypertension.

Pathways for genes affiliated with Chronic Thromboembolic Pulmonary Hypertension

About this section

Pathways related to Chronic Thromboembolic Pulmonary Hypertension according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.5BMPR2, NPPB
29.2EDN1, NPPB
39.1EDN1, PTGIS
4
Show member pathways
9.0CRP, EDN1

GO Terms for genes affiliated with Chronic Thromboembolic Pulmonary Hypertension

About this section

Biological processes related to Chronic Thromboembolic Pulmonary Hypertension according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cellular response to interleukin-6GO:00713549.9FGA, PTGIS
2prostaglandin biosynthetic processGO:00015169.6EDN1, PTGIS
3negative regulation of cell growthGO:00303089.5BMPR2, NPPB
4positive regulation of urine volumeGO:00358109.4EDN1, NPPB

Sources for Chronic Thromboembolic Pulmonary Hypertension

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet